Latest Fda Regulation News

Page 1 of 5
AdAlta has taken ownership of the US FDA Orphan Drug Designation for EW-001, strengthening the commercial case for its mesothelioma CAR-T therapy. The designation follows a constructive pre-IND meeting, but approval and clinical success remain unproven.
Ada Torres
Ada Torres
17 Nov 2026
Vectus Biosystems has received supportive written FDA feedback on VB0004, reducing uncertainty around the drug candidate’s manufacturing, nonclinical and planned clinical development package. The company will now incorporate the guidance into an IND application for a Phase Ib/IIa study in IPF patients in Australia.
Ada Torres
Ada Torres
16 Nov 2026
Neurizon’s first participant in the 250-person Regimen I ALS trial has completed the 36-week randomised phase and entered an optional active treatment extension. The milestone keeps the program on track for topline results in late Q2 2027, while recent FDA feedback points to a potential single-trial approval pathway if the data meet regulatory standards.
Ada Torres
Ada Torres
13 Nov 2026
Imricor Medical Systems (ASX:IMR) has moved from regulatory preparation into US commercial deployment, signing its first two NorthStar hospital customers within weeks of launch. The milestone comes with sharply higher quarterly revenue, a fresh Philips pathway and a still-heavy cash burn.
Victor Sage
Victor Sage
13 Nov 2026
Artrya has signed its first inbound US customer outside its foundation and research relationships, securing a five-year HonorHealth agreement with a minimum value of US$0.5 million. The Salix platform will be deployed across the Arizona health system’s nine-hospital CCTA network.
Victor Sage
Victor Sage
13 Nov 2026
Cleo Diagnostics has commissioned three Ella immunoassay instruments at a US laboratory as it prepares to begin the final major clinical testing program for its pre-surgical ovarian cancer test. The approximately 1,470-sample program is intended to support a planned FDA 510(k) submission in the first half of calendar 2027, but no clinical results have yet been reported.
Ada Torres
Ada Torres
12 Nov 2026
Radiopharm Theranostics has reached final alignment with the U.S. FDA on a single pivotal Phase 3 trial for RAD101, its brain metastases imaging agent. The approximately 280-patient study is expected to begin dosing in the first half of 2027, moving the program from regulatory planning towards execution.
Ada Torres
Ada Torres
4 Nov 2026
Percheron Therapeutics has received a US FDA Safe to Proceed letter for Vanderbilt Health to begin an investigator-sponsored trial of HMBD-002 in combination with venetoclax and azacitidine. The early-stage study will target up to 20 patients with relapsed or refractory AML or AML with MDS.
Ada Torres
Ada Torres
2 Nov 2026
Alterity Therapeutics says it has begun operational preparations for a Phase 3 ATH434 trial after FDA minutes confirmed the proposed design and registrational pathway in Multiple System Atrophy. The company ended September with A$41.3 million in cash, while a new US patent extends protection for ATH434 to 2045.
Ada Torres
Ada Torres
30 Oct 2026
Optiscan has moved its InForm and InVue medical-imaging devices into formal US FDA review after a quarter of intensive regulatory and clinical work. The milestone comes with $11.093 million in cash and a reported 3.5 quarters of funding at the latest operating burn rate.
Victor Sage
Victor Sage
30 Oct 2026
Vectus Biosystems has secured FDA acceptance of a pre-IND Type B meeting for VB0004, a key regulatory step for its idiopathic pulmonary fibrosis programme. The biotech ended September with $410,000 in cash and reported estimated funding for just 1.33 quarters of operations.
Ada Torres
Ada Torres
29 Oct 2026
Mesoblast has posted a 44% rise in first-quarter Ryoncil revenue to US$28 million while sharply reducing operating cash use. The biotechnology company also completed treatment in its 350-patient chronic low back pain trial and received FDA confirmation that a heart-failure BLA filing may proceed.
Ada Torres
Ada Torres
29 Oct 2026

Browse the archive

Full archive